valsartan has been researched along with nitrates in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, ZJ; Fiebeler, A; Ganten, D; Ganten, U; Lapatto, R; Luft, FC; Mervaala, EM; Müller, DN; Nurminen, K; Tikkanen, I; Vapaatalo, H | 1 |
| Abadir, PM; Carey, RM; Siragy, HM | 1 |
| Imanishi, M; Kitabayashi, C; Konishi, Y; Maeda, I; Masada, M; Morikawa, T; Nishiyama, A; Okada, N; Shirahashi, N; Wilcox, CS | 1 |
| Burgin, K; Daiber, A; Daub, S; Gori, T; Hausding, M; Knorr, M; Kröller-Schön, S; Münzel, T; Oelze, M; Rümmler, R; Sartor, D; Scherhag, A; Schreiner, J; Schuff, A; Schulz, E; Wenzel, P | 1 |
| Butler, J; Hamo, CE; Papadimitriou, L | 1 |
| Burgin, K; Daiber, A; Gori, T; Jansen, T; Knorr, M; Kopp, M; Kröller-Schön, S; Münzel, T; Oelze, M; Sartor, D; Scherhag, A; Schulz, E; Stamm, P; Tran, LP; Ullmann, E; Welschof, P | 1 |
| Heidenreich, PA; Kohsaka, S; Lewis, EF; Sandhu, AT; Turakhia, MP | 1 |
1 review(s) available for valsartan and nitrates
| Article | Year |
|---|---|
Heart Failure Guidelines on Pharmacotherapy.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Diuretics; Drug Combinations; Heart Failure; Humans; Hydralazine; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Nitrates; Practice Guidelines as Topic; Severity of Illness Index; Stroke Volume; Tetrazoles; Valsartan; Vasodilator Agents | 2017 |
1 trial(s) available for valsartan and nitrates
| Article | Year |
|---|---|
Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Angiotensin Receptor Antagonists; Biopterins; Blood Pressure; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Hemodynamics; Humans; Kidney; Male; Middle Aged; Nitrates; Nitric Oxide; Nitrites; Receptors, Angiotensin; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2013 |
5 other study(ies) available for valsartan and nitrates
| Article | Year |
|---|---|
Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes.
Topics: Acetylcholine; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensive Agents; Dinoprost; Disease Models, Animal; Endothelium, Vascular; F2-Isoprostanes; Humans; Hypertension; Ketone Oxidoreductases; Male; Nitrates; Nitrites; Nitroprusside; Norepinephrine; Rats; Rats, Sprague-Dawley; Renal Artery; Renin; Superoxide Dismutase; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents; Vasodilation | 2001 |
Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cyclic GMP; Extracellular Space; Imidazoles; Kidney; Mice; Mice, Knockout; Nitrates; Nitric Oxide; Nitrites; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Receptors, Angiotensin; Receptors, Bradykinin; Sodium; Tetrazoles; Valine; Valsartan | 2003 |
Characterization of new organic nitrate hybrid drugs covalently bound to valsartan and cilostazol.
Topics: Animals; Cilostazol; Male; Nitrates; Oxidative Stress; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan; Vasoconstriction; Vasodilator Agents | 2012 |
Basic in vitro Characterization of the Vasodilatory Potential of 2-Aminoethyl Nitrate Fixed-Dose Combinations with Cilostazol, Metoprolol and Valsartan.
Topics: Animals; Aorta; Cilostazol; Drug Combinations; Drug Synergism; Male; Metoprolol; Mitochondria, Heart; Nitrates; Oxidative Stress; Rats, Wistar; Tetrazoles; Valsartan; Vasodilator Agents | 2018 |
Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Female; Guideline Adherence; Heart Failure; Humans; Hydralazine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Mortality; Nitrates; Practice Guidelines as Topic; Quality of Health Care; Stroke Volume; United States; United States Department of Veterans Affairs; Valsartan; Veterans | 2022 |